Anthem Biosciences Limited (BOM:544449)
India · Delayed Price · Currency is INR | Market Cap | 499.58B +17.2% |
| Revenue (ttm) | 20.07B -2.2% |
| Net Income | 5.76B +14.1% |
| EPS | 10.11 +12.5% |
| Shares Out | n/a |
| PE Ratio | 86.74 |
| Forward PE | 66.53 |
| Dividend | 2.00 (0.22%) |
| Ex-Dividend Date | Jun 25, 2026 |
| Volume | 166,823 |
| Open | 850.00 |
| Previous Close | 851.95 |
| Day's Range | 842.55 - 895.95 |
| 52-Week Range | 579.45 - 977.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 905.13 (+1.75%) |
| Est. Earnings | Oct 21, 2026 |
About Anthem Biosciences
Anthem Biosciences Limited operates as a contract research, development, and manufacturing organization in India, rest of Asia, North America, Europe, and internationally. It operates in two segments: Contract Manufacturing, Development & Discovery Services; and Speciality Ingredients. The company offers contract research development and manufacturing services, such as end-to-end services across the new chemical entity and new biological entity lifecycles, as well as engages in contract research, development, and manufacturing of development ba... [Read more]
Financial Performance
In fiscal year 2026, Anthem Biosciences's revenue was 21.29 billion, an increase of 15.09% compared to the previous year's 18.50 billion. Earnings were 5.92 billion, an increase of 31.14%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for 544449 stock is "Strong Buy." The 12-month stock price target is ₹905.13, which is an increase of 1.75% from the latest price.
News
Anthem Biosciences Transcript: Q1 26/27
Q1 FY 2027 saw revenue of INR 418 crores with strong margins, though revenue declined year-over-year due to deferred deliveries. Growth is expected to rebound in subsequent quarters, supported by a robust order book, ongoing capacity expansion, and continued margin discipline.
Anthem Biosciences Quarterly report: Q1 2027
Anthem Biosciences has published its Q1 2027 quarterly earnings report on July 22, 2026.
Anthem Biosciences Slides: Q1 2027
Anthem Biosciences has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 22, 2026.
Anthem Biosciences Transcript: Q4 25/26
FY 2026 saw 18% revenue growth, record Q4 results, and strong margin expansion, driven by CRDMO and Specialty Ingredients. Capacity expansions and robust cash position support future growth, with management targeting 20%+ growth and maintaining high margins.
Anthem Biosciences Quarterly report: Q4 2026
Anthem Biosciences has published its Q4 2026 quarterly earnings report on May 20, 2026.
Anthem Biosciences Slides: Q4 2026
Anthem Biosciences has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 20, 2026.
Anthem Biosciences Annual report: Q4 2026
Anthem Biosciences has published its Q4 2026 annual report on May 20, 2026.
Anthem Biosciences Transcript: Q3 25/26
Revenue for the nine months reached INR 1,513 crore with strong EBITDA margins above 41% and PAT margin at 24.8%. Management expects mid-teen revenue growth for FY 2026, with margin improvements sustained by backward integration and robust demand outlook.
Anthem Biosciences Quarterly report: Q3 2026
Anthem Biosciences has published its Q3 2026 quarterly earnings report on February 5, 2026.
Anthem Biosciences Slides: Q3 2026
Anthem Biosciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 5, 2026.
Anthem Biosciences Transcript: Q2 25/26
Revenue and EBITDA grew strongly in H1 FY2026, driven by CRDMO, with margins at 41.4%. Four new commercial molecules were added, capacity expansions are on track, and management expects continued growth and robust margins for the year.
Anthem Biosciences Quarterly report: Q2 2026
Anthem Biosciences has published its Q2 2026 quarterly earnings report on November 8, 2025.
Anthem Biosciences Slides: Q2 2026
Anthem Biosciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 8, 2025.